Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET

Company Participants

Matthew Scalo - SVP, Investor Relations

Paul Diaz - CEO, President & Director

Nicole Lambert - COO

Bryan Riggsbee - EVP, CFO & Treasurer

Conference Call Participants

Daniel Brennan - Life Science & Diagnostic Tools

Matthew Sykes - Goldman Sachs

Jack Meehan - Nephron Research

Mason Carrico - Stephens Incorporated

Brandon Couillard - Jefferies

Julia Kim - JPMorgan

Puneet Souda - SVB Securities

Operator

Greetings, and welcome to the Myriad Genetics Third Quarter 2022 Financial Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded today, Tuesday, November 1, 2022.

I would now like to turn the conference over to Matt Scalo. Please go ahead.

Matthew Scalo

Thanks Grant. And good afternoon, and welcome to the Myriad Genetics' Third Quarter 2022 Earnings Call. During the call, we'll review the financial results we released today. And afterwards, we'll host a Q&A session. Our quarterly earnings release was issued this morning in Form 8-K and can be found on our website at investor.myriad.com.

I'm Matt Scalo, Senior Vice President of Investor Relations. And on the call with me today is Paul Diaz, our President and Chief Executive Officer; Bryan Riggsbee, our Chief Financial Officer; and Nicole Lambert, our Chief Operating Officer. This call will be heard via live via webcast at investor.myriad.com. And a recording will be archived in the investor section of our website along with this slide presentation. Please note that some of the information presented today contains projections or other forward-looking statements regarding future events, or the future financial performance of the company. These statements are based on management's current expectations, and the actual events or results may differ materially and adversely from the expectations for a variety of reasons. We refer you to the documents the company files from time to time with the SEC, specifically, the company's annual report on Form 10-K, it’s quarterly reports on Form 10-Q and the current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections, or forward looking statements.

With that, I'll turn the call over to Paul.

Paul Diaz

Thanks, Matt. Good afternoon, everyone. And thank you for joining us. On today's call we will discuss our Q3 results, along with highlights from the quarter and updates on our strategic transformation and growth plan. I want to start by thanking all of our teammates for their hard work and dedication this quarter, to advancing our mission and our vision to make genetic testing and precision medicine more accessible to help people take more control of their health and enable providers to better detect, treat and prevent disease.